Zidovudine

證據等級: L5

預測適應症: 6 個

Zidovudine: From HIV/AIDS Antiretroviral Therapy to Feline Acquired Immunodeficiency Syndrome

One-Sentence Summary

Zidovudine (AZT/ZDV) is the original nucleoside reverse transcriptase inhibitor (NRTI), globally established as an antiretroviral for HIV/AIDS in humans — though this specific evidence pack contains no formal record of that original indication. The TxGNN model's top-ranked prediction is feline acquired immunodeficiency syndrome (FIV/FAIDS), a veterinary (non-human) disease, supported only by 20 preclinical animal-model publications and zero clinical trials. Because the top-scoring candidate is not a human indication, this signal is not actionable for human drug repurposing in its current form.

Quick Overview

Item	Content
Original Indication	Not recorded in source data (drug not locally marketed); zidovudine is internationally documented as the first NRTI antiretroviral for HIV/AIDS
Predicted New Indication	Feline Acquired Immunodeficiency Syndrome (veterinary indication — not applicable to human patients)
TxGNN Prediction Score	99.96%
Evidence Level	L4 (preclinical/animal-model literature only; not translatable to human indication)
Norway Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in this evidence pack (original_moa: Data Gap). Based on the extensive literature returned across all ranked indications, zidovudine is consistently described as a thymidine-analogue nucleoside reverse transcriptase inhibitor (NRTI) — it is phosphorylated intracellularly and incorporated by retroviral reverse transcriptase, terminating proviral DNA synthesis. This mechanism is species-agnostic at the enzyme level, which explains why the drug shows anti-retroviral activity not only against HIV-1 in humans but also against related lentiviruses in other species.

This mechanistic non-specificity is exactly why the top two TxGNN predictions — feline acquired immunodeficiency syndrome (rank 1, score 0.9996) and simian immunodeficiency virus infection (rank 2, nearly identical score 0.9996) — score so highly: the knowledge graph links zidovudine to these entities through decades of comparative-virology literature in which cats and macaques were used as experimental animal models for HIV/AIDS drug development, not because zidovudine is a clinically indicated therapy for pet or primate disease. In other words, the model is picking up literature co-occurrence from preclinical model systems, not a genuine new human therapeutic opportunity.

By contrast, ranks 5 and 6 in this same evidence pack — AIDS related complex and congenital human immunodeficiency virus — are strongly supported by dozens of completed Phase 1–3 human trials (including the landmark ACTG 076 trial for perinatal transmission prevention) and are, in fact, already established human uses of zidovudine rather than novel repurposing candidates. Ranks 3 and 4 (a rare neurodevelopmental syndrome and "obsolete familial combined hyperlipidemia") have already been internally flagged with no mechanistic link, and for rank 4 the plausible relationship runs in the opposite direction — NRTI therapy is associated with lipodystrophy/dyslipidemia as an adverse effect, not a treatment benefit. Taken together, this candidate bundle illustrates a case where raw TxGNN ranking, without species and clinical-context filtering, surfaces model artifacts rather than viable repurposing signals.

Clinical Trial Evidence

Currently no related clinical trials registered for feline acquired immunodeficiency syndrome (as expected — this is a veterinary indication and would not appear in ClinicalTrials.gov/ICTRP for human subjects).

Literature Evidence

All available literature for this indication consists of preclinical animal-model studies in domestic cats; none are human clinical trials, RCTs, or reviews.

PMID	Year	Type	Journal	Key Findings
2475068	1989	Preclinical (feline model)	Antimicrob Agents Chemother	Established FIV as a model for AZT-based reverse-transcriptase-targeted chemotherapy for human AIDS
3034403	1987	Preclinical (feline model)	Cancer Research	Early evaluation of AZT in FeLV-infected cats as a therapy/prophylaxis model for AIDS
2178336	1990	Preclinical (feline model)	Antimicrob Agents Chemother	Interferon-alpha plus AZT evaluated in presymptomatic feline leukemia virus-induced AIDS (FAIDS)
2163339	1990	Preclinical (feline model, toxicology)	Fundam Appl Toxicol	Dose-ranging toxicity study of AZT in FeLV-infected cats
8381867	1993	Preclinical (feline model)	J Acquir Immune Defic Syndr	Prophylactic AZT reduced early viremia and lymphocyte decline but did not prevent primary FIV infection
7688949	1993	Preclinical (feline model)	Arch Virol	AZT and cyclosporine reduced plasma (but not PBMC) FIV titers
11943320	2002	Preclinical (feline model)	Vet Immunol Immunopathol	AZT/3TC combination showed additive-to-synergistic anti-FIV activity in vitro; questioned efficacy in chronic infection
18550661	2008	Preclinical (feline model, genetics)	J Virol	Phylogenetic analysis of FIV genes in cats undergoing AZT treatment vs. treatment-naïve cats
22816032	2012	Preclinical (feline model)	Viruses	Compared AZT alone vs. AZT combinations (IFN-α, 3TC, valproic acid) in naturally FIV-infected cats over one year
25855689	2016	Preclinical (feline model, long-term)	J Feline Med Surg	Long-term (5–6 year) follow-up of AZT-based antiretroviral therapy in FIV-infected cats

Norway Market Information

This drug currently has no authorizations on file for this market (market_status: Not Marketed; total_licenses: 0). No product listings are available to summarize.

Safety Considerations

Please refer to the package insert for safety information. No structured warnings, contraindications, or drug-interaction data are currently available in the evidence pack (key_warnings, contraindications, and DDI queries all returned no data). This is flagged as a Blocking data gap (DG001) — official label/monograph data must be sourced before this candidate can proceed through initial safety screening (S1).

Conclusion and Next Steps

Decision: Hold

Rationale: The highest-ranked TxGNN prediction (feline acquired immunodeficiency syndrome) is a veterinary, non-human indication with no clinical trial evidence and only preclinical animal-model literature — it is not actionable as a human drug repurposing candidate. Combined with a Blocking safety data gap (no label/warnings data) and the drug's absence from the local market, there is insufficient basis to advance.

To proceed, the following is needed:

Official product label / TFDA-equivalent monograph data (warnings, contraindications, DDIs) to close the Blocking data gap (DG001)
Confirmed mechanism-of-action documentation (DG002)
Species/entity filtering on TxGNN outputs to exclude non-human disease terms before ranking is presented for human repurposing review
If pursued further, reassessment should focus on the lower-ranked but clinically grounded signals in this pack (AIDS related complex, congenital HIV infection) — noting these reflect zidovudine's already established human use rather than a novel repurposing opportunity, so they would not qualify as new indications either
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.